{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kostopoulos N"],"funding":["NCI NIH HHS"],"pagination":["6308-6320"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11700247"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(24)"],"pubmed_abstract":["<h4>Abstract</h4>Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CART-19) represents a significant advance in the treatment of patients with relapsed or refractory CD19+ B-cell lymphomas. However, a significant portion of patients either relapse or fail to respond. Moreover, many patients have symptomatic disease, requiring bridging radiation therapy (RT) during the period of CAR T-cell manufacturing. To investigate the impact of 1 to 2 fractions of low-dose RT on CART-19 treatment response, we developed a mouse model using A20 lymphoma cells for CART-19 therapy. We found that low-dose fractionated RT had a positive effect on generating abscopal systemic antitumor responses beyond the irradiated site. The combination of RT with CART-19 therapy resulted in additive effects on"],"journal":["Blood advances"],"pubmed_title":["Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration."],"pmcid":["PMC11700247"],"funding_grant_id":["R01 CA206012"],"pubmed_authors":["Facciabene A","Thyfronitis G","LaRiviere MJ","Chong EA","Koumenis C","Beghi S","Schuster SJ","Krimitza E","Kostopoulos N","Costabile F","Goia D","Perales-Linares R","Plastaras JP","Maity A"],"additional_accession":[]},"is_claimable":false,"name":"Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration.","description":"<h4>Abstract</h4>Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CART-19) represents a significant advance in the treatment of patients with relapsed or refractory CD19+ B-cell lymphomas. However, a significant portion of patients either relapse or fail to respond. Moreover, many patients have symptomatic disease, requiring bridging radiation therapy (RT) during the period of CAR T-cell manufacturing. To investigate the impact of 1 to 2 fractions of low-dose RT on CART-19 treatment response, we developed a mouse model using A20 lymphoma cells for CART-19 therapy. We found that low-dose fractionated RT had a positive effect on generating abscopal systemic antitumor responses beyond the irradiated site. The combination of RT with CART-19 therapy resulted in additive effects on","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-06-01T23:13:15.814Z","creation":"2026-05-23T03:08:08.636Z"},"accession":"S-EPMC11700247","cross_references":{"pubmed":["39213422"],"doi":["10.1182/bloodadvances.2024012599"]}}